Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment.
Atherocardiovascular disease
Growth hormone treatment
Lipoprotein(a)
Journal
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
14
08
2022
accepted:
05
09
2022
pubmed:
18
9
2022
medline:
18
11
2022
entrez:
17
9
2022
Statut:
ppublish
Résumé
A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the recently reported association between childhood hGH treatment and cardiovascular morbidity is probably due to the GH effect on Lp(a) synthesis. It is therefore suggested to determine serum Lp(a) levels before and during hGH treatment in children and adults.
Identifiants
pubmed: 36115257
pii: S1096-6374(22)00060-0
doi: 10.1016/j.ghir.2022.101503
pii:
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Lipoprotein(a)
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101503Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.